Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TAG Oil prepares for flow testing of its first unconventional oil well in Egypt (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News InflaRx NV IFRX

Healthcare Biotechnology
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously... see more

Recent & Breaking News (NDAQ:IFRX)

InflaRx Reports Full Year 2023 Results and Announces INF904 Development Plans

GlobeNewswire March 21, 2024

InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024

GlobeNewswire March 19, 2024

InflaRx Appoints Jan Medina as Head of Investor Relations

GlobeNewswire February 22, 2024

InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible Patients

GlobeNewswire January 25, 2024

InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904

GlobeNewswire January 4, 2024

InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum

GlobeNewswire November 6, 2023

InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 1, 2023

InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904

GlobeNewswire September 11, 2023

InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)

GlobeNewswire August 30, 2023

InflaRx Reports Second Quarter 2023 Financial Results & Operating Update

GlobeNewswire August 10, 2023

InflaRx Appoints Dr. Camilla Chong as Chief Medical Officer

GlobeNewswire June 28, 2023

InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 Patients

GlobeNewswire June 21, 2023

InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business Update

GlobeNewswire May 11, 2023

InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 million

GlobeNewswire April 18, 2023

InflaRx Announces Closing of $40 Million Public Offering of Ordinary Shares

GlobeNewswire April 14, 2023

InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares

GlobeNewswire April 11, 2023

InflaRx Announces Public Offering of Ordinary Shares

GlobeNewswire April 11, 2023

InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

GlobeNewswire April 4, 2023

InflaRx Reports Full Year 2022 Financial and Operating Results

GlobeNewswire March 22, 2023

InflaRx Provides Update on Planned Phase III Study Design in Pyoderma Gangrenosum with Vilobelimab and Status of its EUA Application in Critically Ill COVID-19 Patients

GlobeNewswire January 5, 2023